Loading company…
Selecxine develops antibody-based immunotherapies for cancer.
Founded in 2018 and based in Pohang, South Korea, Selecxine develops anti-cancer immunotherapeutics using antibody platform technology. Its SLC-3010 platform is based on an anti-human IL-2 antibody. In May 2020, the company raised KRW 13.7 billion in Series A funding from BM Ventures, Hanwha Investment & Securities, K-Run Ventures, Lighthouse Combined Investment, Medytox Venture Investment, POSCO Capital, Quantum Ventures Korea, SJ Investment Partners and Stonebridge Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in